ProPhase Q1 net loss narrows to $4.7M, cuts costs, eyes Nebula sale, $50M recovery

ProPhase Labs, Inc.

2025-Q1 EPS reported $0.11 vs consensus -$1.84 ▲ beat (+106.0%)

Q1 net revenue $1.4M (down from $2.4M YoY); net loss $4.7M ($0.13/shr) vs $5.5M loss ($0.32/shr) last year.
Headcount slashed from 96 to 25; Pharmaloz divested for ~$23M, genomics lab closed, saving >$6M annually.
Engaged ThinkEquity to sell Nebula Genomics; 16-petabyte DNA dataset; sale expected within 3-4 months.
Crown Medical expects ~$50M in insurance recoveries; company carries $20M A/R for this initiative.
BE-Smart esophageal test submitted for peer review; LDT rule vacated by federal judge on Apr 1, 2025.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.